Drugs named for third cycle of Medicare negotiations

The US Centers for Medicare & Medicaid Services (CMS) has announced the selection of 15 high-cost prescription medicines covered under Medicare Part D and—for the first time—those payable under Medicare Part B, for the third cycle of the Medicare Drug Price Negotiation Program.

CMS has also selected one previously negotiated drug for the program’s first renegotiations. Negotiations with participating drug companies will occur this year, and any negotiated and renegotiated prices will become effective January 1, 2028. 

This announcement has been billed as the Trump Administration’s latest effort to reduce prescription drug costs.